Here are the 10-K annual reports from Alkermes Inc. plc (ALKS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ALKS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALKS filings page.
Alkermes plc describes a global neuroscience-focused biopharmaceutical business built around proprietary drugs for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, plus licensed and technology-partnered products.
The company completed the acquisition of Avadel Pharmaceuticals in February 2026, adding LUMRYZ, the first once-at-bedtime sodium oxybate for narcolepsy, and a dedicated commercial organization. Alkermes highlights key products ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL, royalty-generating collaborations with Janssen and Biogen, and a late-stage pipeline led by alixorexton, an orexin 2 receptor agonist with FDA Breakthrough Therapy designation in narcolepsy. The filing also outlines extensive patent protection, manufacturing arrangements, intense competitive pressures and numerous business risks, including reliance on a few major products, regulatory and IP challenges, debt obligations and potential volatility in its ordinary shares.